Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequencemarketing2021-02-11T23:36:10+00:00November 13th, 2019|2019 Publications, Publications| 続きを読む
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implicationsmarketing2021-02-11T23:40:44+00:00October 15th, 2019|2019 Publications, Publications| 続きを読む
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myelomamarketing2021-02-11T23:43:09+00:00October 1st, 2019|2019 Publications, Publications| 続きを読む
Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myelomamarketing2021-02-15T20:01:10+00:00June 6th, 2019|2019 Publications, Publications| 続きを読む
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasmsmarketing2021-02-11T23:46:14+00:00March 21st, 2019|2019 Publications, Featured Publications, Publications| 続きを読む
